Therapeutic patents for the treatment of premenstrual syndrome and premenstrual dysphoric disorder: historical perspectives and future directions

Bibliography

• MASON-HOHL E: The Diseases of Women by Trotula of Salerno, a Translation of Passionibus Muliemm Curandorum. The Ward Ritchie Press (1940).
   Google Scholar
• FRANK RT: The hormonal causes of premenstrual tension. Arch. Neurol Psychiatry(1931) 26:1053–1057.
   Google Scholar
• •The first description in the medical literature of the syndrome of premenstrual tension.
   Google Scholar
• DALTON K: The Premenstrual Syndrome. William Heineman Medical Books, London, UK (1964).
   Google Scholar
• •A classic monograph describing the impact of the menstrual cycle on psychiatric and medical disorders.
   Google Scholar
• DELANEY J, LUPTON MJ, TOTH E: The Curse: a Cultural History of Menstruation. EP Dutton & Co., Inc., New York, USA (1976).
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders Ord edn). American Psychiatric Press, Washington, DC, USA (1987):367–369.
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders (4th edn). American Psychiatric Press, Washington, DC, USA (1994):771–774.
   Google Scholar
• WORLD HEALTH ORGANIZATION: International Classification of Diseases HOth edn). World Health Organization, Geneva, Switzerland (1996).
   Google Scholar
• WOODS NE MOST A, DERY GK: Prevalence of perimenstrual symptoms. Am. .1. Public Health (1982) 72 (11):1257–1264.
   Google Scholar
• RIVERA-TOVAR AD, FRANK E: Late luteal phase dysphoric disorder in young women. Am. J. Psychiatry (1990) 147(12):1634–1636.
   PubMed Web of Science ®Google Scholar
• ANGST J, SELLARO R, MERIKAN GAS KR, ENDICOTT J: The epidemiology of perimenstrual psychological symptoms. Acta Psychiati: Scand. (2001) 104(2):110–116.
   PubMed Web of Science ®Google Scholar
• COHEN LS, SOARES CN, OTTO MW, SWEENEY BH, LIBERMAN RF, HARLOW BL: Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. Affect. Disord. (2002) 70(2):125–132.
   PubMed Web of Science ®Google Scholar
• WITTCHEN HU, BECKER E, LIEB R, KRAUSE P: Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psycho]. Med. (2002) 32(1):119–132.
   PubMed Web of Science ®Google Scholar
• ROSS LE, STEINER M: A boipsychosocial approach to premenstrual dysphoric disorder. Psychiatr. Clin. N Am. (2003) 26:529–546.
   PubMed Web of Science ®Google Scholar
• ROCA CA, SCHMIDT PJ, BLOCH M, RUBINOW DR: Implications of endocrine studies of premenstrual syndrome. Psychiatr. Ann. (1996) 26:576–580.
   Web of Science ®Google Scholar
• RUBINOW DR, SCHMIDT PJ: The treatment of premenstrual syndrome - forward into the past. N Engl. I Med. (1995) 332(23):1574–1575.
   PubMed Web of Science ®Google Scholar
• SCHMIDT PJ, NIEMAN LK, DANACEAU MA, ADAMS LF, RUBINOW DR Differential behavioural effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl. I Med. (1998) 338(4):209–216.
   PubMed Web of Science ®Google Scholar
• •An elegant study, which demonstrated that women with PMS show differential sensitivity to sex hormones.
   Google Scholar
• ERIKSSON E, SUNDBLAD C, LANDEN M, STEINER M: Behavioural effects of androgens in women. In: Mood Disorders in Women. Steiner M, Yonkers KA, Eriksson E (Eds), Martin Dunitz Ltd, London, UK (2000):233–246.
   Google Scholar
• SUNDSTROM POROMAA I, SMITH S, GULINELLO M: GABA receptors, progesterone and premenstrual dysphoric disorder. Arch. Women Ment. Health (2003) 6(1):23–41.
   PubMedGoogle Scholar
• ISRAEL SL: Premenstrual tension. JAMA (1938) 110(21):1721–1723.
   Google Scholar
• BACKSTROM T, ANDREEN L, BIRZNIECE V et al.: The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs (2003) 17(5):325–342.
   PubMed Web of Science ®Google Scholar
• JANOWSKY DS, GORNEY R, KELLEY B: "The curse" - vicissitudes and variations of the female fertility cycle. Part I. Psychiatric aspects. Psychosomatics (1966) 7(4):242–247.
   Google Scholar
• GRAHAM CA, SHERWIN BB: The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology (1993) 18(4):273–281.
   PubMed Web of Science ®Google Scholar
• GRAHAM CA, SHERWIN BB: A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J. Psychosom. Res. (1992) 36(3)257–266.
   Google Scholar
• KAHN LS, HALBREICH U: Oral contraceptives and mood. Expert Opin. Pharmacother: (2001) 2(9):1367–1382.
   PubMedGoogle Scholar
• FREEMAN EW, KROLL R, RAPKIN A et al.: Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. Womens Health Gend. Based Med. (2001) 10(6):561–569.
   PubMedGoogle Scholar
• BROWN C, LING F, WAN J: A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. J. Reprvd. Med. (2002) 47(1):14–22.
   Google Scholar
• BORENSTEIN J, YU HT, WADE S, CHIOU CF, RAPKIN A: Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. .1 Reprod. Med. (2003) 48(2):79–85.
   Google Scholar
• FREEMAN EW, SONDHEIMER SJ, RICKELS K: Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull. (1997) 33(2):303–309.
   PubMedGoogle Scholar
• BROWN CS, LING FW, ANDERSEN RN, FARMER RG, ARHEART KL: Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet. GynecoL (1994) 84(5):779–786.
   PubMed Web of Science ®Google Scholar
• HAMMARBACK S, BACKSTROM T: Induced anovulation as treatment of premenstrual tension syndrome: a double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet. GynecoL Scand. (1988) 67(2):159–166.
   PubMed Web of Science ®Google Scholar
• HUSSAIN SY, MASSIL JH, MATTA WH, SHAW RW, O'BRIEN PM: Buserelin in premenstrual syndrome. Gynecol Endocrinol (1992) 6(1):57–64.
   PubMed Web of Science ®Google Scholar
• FENTIMAN IS, CALEFFI M, BRAME K, CHAUDARY MA, HAYVVARD JL: Double-blind controlled trial of tamoxifen therapy for mastalgia. Lancet (1986) 1(8476):287–288.
   PubMed Web of Science ®Google Scholar
• GRIFFIN LD, CONRAD SC, MELLON SH: Current perspectives on the role of neurosteroids in PMS and depression. hat. Rev Neurobiol (2001) 464:79–492.
   Google Scholar
• SMITH S, RINEHART JS, RUDDOCK VE, SCHIFF I: Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet. GynecoL (1987) 70(1):37–43.
   PubMed Web of Science ®Google Scholar
• HARRISON WM, ENDICOTT J, NEE J: Treatment of premenstrual dysphoria with alprazolam: a controlled study. Arch. Gen. Psychiatry (1990) 47(3):270–275.
   PubMed Web of Science ®Google Scholar
• SCHMIDT PJ, GROVER GN, RUBINOW DR: Alprazolam in the treatment of premenstual syndrome: a double-blind, placebo-controlled trial. Arch. Gen. Psychiatry (1993) 50 (6):467–473.
   PubMed Web of Science ®Google Scholar
• WANG M, SEIPPEL L, PURDY RH, BACKSTROM T: Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5a-pregnane-3,20-dione and 3a-hydroxy-5a- pregnan-20-one. Clin. Endocrinol Metab. (1996) 81(3):1076–1082.
   Google Scholar
• RAPKIN AJ, MORGAN M, GOLDMAN L, BRANN DW, SIMONE D, MAHESH VB: Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet. Gynecol (1997) 90(5):709–714.
   PubMed Web of Science ®Google Scholar
• MONTELEONE P, LUISI S, TONETTI A et al.: Allopregnanolone concentrations and premenstrual syndrome. Ear: Endocrinol (2000) 142(3):269–273.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, FRYE CA, RICKELS K, MARTIN PA, SMITH SS: Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. J. Clin. Psychopharmacol (2002) 22(5):516–520.
   PubMed Web of Science ®Google Scholar
• GASIOR M, CARTER RB, WITKIN JM: Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol Sci. (1999) 20(3):107–112.
   PubMed Web of Science ®Google Scholar
• NICOLSON A, LEACH JP: Future prospects for the drug treatment of epilepsy. CNS Drugs (2001) 15(12):955–968.
   PubMed Web of Science ®Google Scholar
• FELBERBAUM RE, DIEDRICH K: Gonadotropin-releasing hormone antagonists: will they replace the agonists? Reprod. Biomed. Online (2003) 6(1):43–53.
   Google Scholar
• STEINER M, PEARLSTEIN T: Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. Clin. Psychiatry (2000) 61 (Supp1.12):17–21.
   Google Scholar
• ERIKSSON E, LISJO P, SUNDBLAD C, ANDERSSON K, ANDERSCH B, MODIGH K: Effect of clomipramine on premenstrual syndrome. Acta Psychiatr. Scand. (1990) 81(1):87–88.
   PubMed Web of Science ®Google Scholar
• •The first report of domiprarnine as an effective treatment for PMS. This was a catalyst for further work on the role of the 5-HT system in PMS/PMDD.
   Google Scholar
• SUNDBLAD C, MODIGH K, ANDERSCH B, ERIKSSON E: Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psych/am Scand. (1992) 85(1):39–47.
   PubMed Web of Science ®Google Scholar
• ERIKSSON E, HEDBERG MA, ANDERSCH B, SUNDBLAD C: The serotonin re-uptake inhibitor paroxetine is superior to the noradrenaline re-uptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology (1995) 12(2):167–176.
   PubMed Web of Science ®Google Scholar
• STEINER M, STEINBERG S, STEWART D et al: Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl.I. Med. (1995) 332(23):1529–1534.
   PubMed Web of Science ®Google Scholar
• •This trial established the SSRIs as a safe and well-tolerated therapy for PMDD.
   Google Scholar
• LIN J, THOMPSON DS: Treating premenstrual dysphoric disorder using serotonin agents. Womens Health Gend. Based Med. (2001) 10(8):745–750.
   PubMedGoogle Scholar
• COHEN LS, MINER C, BROWN EW et al.: Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet. Gynecol. (2002) 100(3):435–444.
   PubMed Web of Science ®Google Scholar
• STEINER M, KORZEKWA M, LAMONT J, WILKINS A: Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol. Bull. (1997) 33(4):771–774.
   PubMedGoogle Scholar
• HALBREICH U, BERGERON R, YONKERS KA, FREEMAN E, STOUT AL, COHEN L: Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet. Gynecol. (2002) 100(6):1219–1229.
   PubMed Web of Science ®Google Scholar
• MINER C, BROWN E, MCCRAY S, GONZALES J, WOHLREICH M: Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin. Ther: (2002) 24(3):417–433.
   PubMed Web of Science ®Google Scholar
• PEARLSTEIN T: Selective serotonin re-uptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard? Drugs (2002) 62(13):1869–1885.
   PubMed Web of Science ®Google Scholar
• WYATT KM, DIMMOCK PW, O'BRIEN PM: Selective serotonin re-uptake inhibitors for premenstrual syndrome. Cochrane Database Syst. Rev (2002) (4):CD001396.
   Google Scholar
• FARVOLDEN P, KENNEDY SH, LAM RW: Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future. Expert Opin. Investig. Drugs (2003) 12 (1):65–86.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, RICKELS K, YONKERS KA, KUNZ NR, MCPHERSON M, UPTON GV: Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet. Gynecol (2001) 98(5Pt1):737–744.
   Google Scholar
• HSIAO MC, LIU CY: Effective open-label treatment of premenstrual dysphoric disorder with venlafaxine. Psychiatry Clin. NeuroscL (2003) 57(3):317–321.
   PubMed Web of Science ®Google Scholar
• LANDEN M, ERIKSSON O, SUNDBLAD C, ANDERSCH B, NAESSEN T, ERIKSSON E: Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (2001) 155(3):292–298.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER LS, SMALL GW, HAMILTON SH, BYSTRITSKY A, NEMEROFF CB, MEYERS BS: Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am. j Geriatr. Psychiatry (1997) 5(2):97–106.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER LS, SMALL GW, CLARY CM: Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am. Geriam Psychiatry (2001) 9(4):393–399.
   PubMed Web of Science ®Google Scholar
• SOARES CN, POITRAS JR, PROUTY J, ALEXANDER AB, SHIFREN JL, COHEN LS: Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. I Clin. Psychiatry (2003) 64(4):473–479.
   PubMed Web of Science ®Google Scholar
• AMSTERDAM J, GARCIA-ESPANA F, FAWCETT J et al.: Fluoxetine efficacy in menopausal women with and without oestrogen replacement. Affect. Disord. (1999) 55(1):11–17.
   PubMed Web of Science ®Google Scholar
• YONKERS KA, BRADSHAW KD, HALBREICH U: Oestrogens, progestins and mood. In: Mood Disorders M Women Steiner M, Yonkers KA, Eriksson E (Eds), Martin Dunitz, London, UK (2000):207–232.
   Google Scholar
• STOKES J, MENDELS J: Pyridoxine and premenstrual tension. Lancet (1972) 1(7761):1177–1178.
   PubMed Web of Science ®Google Scholar
• BENDER DA: Non-nutritional uses of vitamin B6. Br. Num. (1999) 81(1):7–20.
   PubMed Web of Science ®Google Scholar
• WYATT KM, DIMMOCK PW, JONES PW, SHAUGHN O'BRIEN PM: Efficacy of vitamin B6 in the treatment of premenstrual syndrome: systematic review. Br. Med. J. (1999) 318(7195):1375–1381.
   PubMedGoogle Scholar
• THYS-JACOBS S: Micronutrients and the premenstrual syndrome: the case for calcium. I Am. Coll Num. (2000) 19(2):220–227.
   PubMed Web of Science ®Google Scholar
• THYS-JACOBS S, CECCARELLI S, BIERMAN A, WEISMAN H, COHEN MA, ALVIR J: Calcium supplementation in premenstrual syndrome: a randomized crossover trial. Gen. Intern. Med. (1989) 4(3):183–189.
   PubMed Web of Science ®Google Scholar
• •This was the first report of an effect of calcium carbonate on premenstrual symptoms.
   Google Scholar
• THYS-JACOBS S, STARKEY P, BERNSTEIN D, TIAN J: Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am. J. Obstet. Gynecol. (1998) 179(2):444–452.
   PubMed Web of Science ®Google Scholar
• PENLAND JG, JOHNSON PE: Dietary calcium and manganese effects on menstrual cycle symptoms. Am. J Obstet. Gynecol. (1993) 168(5):1417–1423.
   PubMed Web of Science ®Google Scholar
• BUDEIRI D, LI WAN PO A, DORNAN JC: Is evening primrose oil of value in the treatment of premenstrual syndrome? Control. Clin. Trials (1996) 17(1):60–68.
   Web of Science ®Google Scholar
• FUGH-BERMAN A, KRONENBERG F: Complementary and alternative medicine (CAM) in reproductive-age women: a review of randomized controlled trials. Reprod. Toxicol (2003) 17(2):137–152.
   PubMed Web of Science ®Google Scholar
• BENASSAYAG C, PERROT-APPLANAT M, FERRE F: Phytoestrogens as modulators of steroid action in target cells. .1 Chromatogr: B Analyt. Technol Biomed. Life ScL (2002) 777(1–2):233–248.
   Google Scholar
• MORTON MS, ARISAKA O, MIYAKE N, MORGAN LD, EVANS BA: Phytoestrogen concentrations in serum from Japanese men and women over 40 years of age. Num. (2002) 132(10):3168–3171.
   Google Scholar
• MERIKANGAS KR, FOELDENYI M, ANGST J: The Zurich Study - XIX. Patterns of menstrual disturbances in the community: results of the Zurich Cohort Study. Ear: Arch. Psychiatry Clin. Neurosci. (1993) 243(1):23–32.
   Google Scholar
• DAN AJ, MONAGLE L: Sociocultural influences on women's experiences of perimenstrual symptoms. In: Premenstrual Dysphorias: Myths and Realities. Gold JH, Severino SK (Eds), American Psychiatric Press, Washington, DC, USA (1994):201–212.
   Google Scholar
• CHANG AM, HOLROYD E, CHAU JP: Premenstrual syndrome in employed Chinese women in Hong Kong. Health Care Women hat. (1995) 16(6):551–561.
   PubMedGoogle Scholar
• JOHNSON TM: Premenstrual syndrome as a western culture-specific disorder. Cult. Med. Psychiatry (1987) 11(3)337–356.
   Google Scholar
• ANSON O: Exploring the bio-psycho-social approach to premenstrual experiences. Soc. Sci. Med. (1999) 49(1):67–80.
   PubMed Web of Science ®Google Scholar
• KRONENBERG F, FUGH-BERMAN A: Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann. Intern. Med. (2002) 137(10805–813.
   Web of Science ®Google Scholar
• NAFTOLIN F, GUADALUPE STANBURY M: Phytoestrogens: are they really estrogen mimics? Feral Stern. (2002) 77(1):15–17.
   Google Scholar
• MITWALLY MF, KAHN LS, HALBREICH U: Pharmacotherapy of premenstrual syndromes and premenstrual dysphoric disorder: current practices. Expert Opin. Pharmacother. (2002) 3(11):1577–1590.
   PubMedGoogle Scholar